Skip to main content
Premium Trial:

Request an Annual Quote

Dicerna Issued Notice of Allowance on Dicer-Substrate Technology

Premium

Dicerna Pharmaceuticals said this week that the US Patent and Trademark Office has issued the company a notice of allowance for a patent application covering its core Dicer-substrate technology.

Dicerna did not provide specific details about the intellectual property, but said that the new allowance “applies to 148 claims and provides exclusivity around both in vivo therapeutic and in vitro uses of Dicer-substrates for reducing mammalian target gene expression, regardless of their specific sequence.”

Developed by researchers at the City of Hope and Integrated DNA Technologies, Dicer-substrates are essentially synthetic RNA duplexes around 27 nucleotides long. In animal studies, they have been shown to be more potent than standard 21-mer siRNAs while avoiding immune stimulation.

Dicerna was founded in 2007 to develop the technology for therapeutic applications (GSN 11/8/2007).

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.